Last reviewed · How we verify
NCT05514457: Dyslexie REMED
Assessment of Visual Dyslexia Remediation Protocols - Dyslexia REMEDIATION
NA trial testing visual stimulation with I pad in Dyslexia in 13 participants. Completed in 15 March 2024.
15 March 2024
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 13 |
| Start date | 17 November 2022 |
| Primary completion | 15 March 2024 |
| Estimated completion | 15 March 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- visual stimulation with I pad
- visual stimulation with lamp
Conditions studied
- Dyslexia — all drugs for Dyslexia →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
Adults 8 to 12, any sex, with Dyslexia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dyslexia is first described as a phonological deficit. Several studies report a neurovisual deficit in dyslexics. Some dyslexics have a visual deficit without phonological impairment, others have a pure phonological deficit, and still others have both types of deficits. From this observation the idea emerged to propose specific remediation protocols for people with visual impairments and to assess their effects on reading. At the theoretical level, if visual stimulation is able to improve reading performance, it is the demonstration of the existence of visual origin of dyslexia. At the clinical level, such a result not only opens the prospect of a different and more adapted rehabilitation for these types of dyslexia, but also the prospect, if the visual deficits are pre-existing to the learning of reading, to use them for early diagnosis and management.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comment on Le Floch & Ropars (2017) 'Left-right asymmetry of the Maxwell spot centroids in adults without and with dyslexia'.
Naudet F, Seidenberg M, Bishop DVM. · · 2024 · cited 3× · PMID 38412972 · DOI 10.1098/rspb.2023.2060
Verify or expand the search:
- PubMed search for NCT05514457
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dyslexia
Currently open trials in the same condition.
- NCT07262853 — Dual Executive Function Training Package · NA · recruiting
- NCT06902610 — Examining the Medium-term Effect on Non Inferiority of the Previous Training With the DMD Poppins Clinical for Cognitive · recruiting
- NCT05996497 — Evaluation of Speech Rhythm Training in Dyslexic Readers Aged 7 to 9 Years · NA · recruiting
- NCT05780853 — A Game-based Neurodevelopmental Assessment for Young Children · recruiting
- NCT03285789 — Dyslexics' Visual Attention Field · NA · active not recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05514457 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 25 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05514457.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing